Digestive and Liver Disease
Volume 42, Issue 4 , Pages 238-244 , April 2010

Clinical implications of novel aspects of biliary pathophysiology

Received 18 November 2009 ,Accepted 11 January 2010.

References 

  1. Alpini G, McGill JM, LaRusso NF. The pathobiology of biliary epithelia. Hepatology. 2002;35:1256–1268
  2. Marzioni M, Glaser SS, Francis H, et al. Functional heterogeneity of cholangiocytes. Semin Liver Dis. 2002;22:227–240
  3. Desmet VJ. Vanishing bile duct disorders. Prog Liver Dis. 1992;10:89–121
  4. Lazaridis KN, Strazzabosco M, LaRusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology. 2004;127:1565–1577
  5. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry for Transplant Recipients: Transplant Data 1991–2000. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation; 2001;
  6. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308–321
  7. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128:1655–1667
  8. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology. 2007;132:415–431
  9. Vierling JM. Biliary victories: studies of isolated biliary epithelial cells. J Lab Clin Med. 1989;113:663–664
  10. Alpini G, Glaser S, Robertson W, et al. Large but not small intrahepatic bile ducts are involved in secretin-regulated ductal bile secretion. Am J Physiol. 1997;272:G1064–G1074
  11. Alpini G, Glaser SS, Ueno Y, et al. Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. Am J Physiol. 1998;274:G767–G775
  12. Alpini G, Roberts S, Kuntz SM, et al. Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. Gastroenterology. 1996;110:1636–1643
  13. Alpini G, Ulrich C, Roberts S, et al. Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation. Am J Physiol. 1997;272:G289–G297
  14. Benedetti A, Bassotti C, Rapino K, et al. A morphometric study of the epithelium lining the rat intrahepatic biliary tree. J Hepatol. 1996;24:335–342
  15. Alpini G, Ulrich CD, Phillips JO, et al. Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation. Am J Physiol. 1994;266:G922–G928
  16. Glaser SS, Rodgers RE, Phinizy JL, et al. Gastrin inhibits secretin-induced ductal secretion by interaction with specific receptors on rat cholangiocytes. Am J Physiol. 1997;273:G1061–G1070
  17. Alvaro D, Mennone A, Boyer JL. Role of kinases and phosphatases in the regulation of fluid secretion and Cl−/HCO3− exchange in cholangiocytes. Am J Physiol. 1997;273:G303–G313
  18. Fitz JG, Basavappa S, McGill J, et al. Regulation of membrane chloride currents in rat bile duct epithelial cells. J Clin Invest. 1993;91:319–328
  19. Alvaro D, Alpini G, Jezequel AM, et al. Role and mechanisms of action of acetylcholine in the regulation of rat cholangiocyte secretory functions. J Clin Invest. 1997;100:1349–1362
  20. Alpini G, Lenzi R, Sarkozi L, et al. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest. 1988;81:569–578
  21. Alpini G, Glaser SS, Rodgers R, et al. Functional expression of the apical Na+-dependent bile acid transporter in large but not small rat cholangiocytes. Gastroenterology. 1997;113:1734–1740
  22. LeSage G, Glaser S, Marucci L, et al. Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from bile duct ligated rat liver. Am J Physiol. 1999;276:G1289–G1301
  23. Lazaridis KN, Pham L, Tietz P, et al. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J Clin Invest. 1997;100:2714–2721
  24. Scheffer GL, Kool M, de Haas M, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest. 2002;82:193–201
  25. Lazaridis KN, Tietz P, Wu T, et al. Alternative splicing of the rat sodium/bile acid transporter changes its cellular localization and transport properties. Proc Natl Acad Sci USA. 2000;97:11092–11097
  26. Ballatori N, Christian WV, Lee JY, et al. OSTalpha–OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology. 2005;42:1270–1279
  27. Alpini G, Ueno Y, Glaser S, et al. Bile acid feeding stimulates proliferative activity of both small and large cholangiocytes through activation and membrane translocation of protein kinase C alpha. Hepatology. 2001;34:868–876
  28. Alpini G, Ueno Y, Glaser SS, et al. Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large rat cholangiocytes. Hepatology. 2001;34:868–876
  29. Alpini G, Glaser S, Ueno Y, et al. Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated ductal secretion. Gastroenterology. 1999;116:179–186
  30. Alpini G, Glaser S, Robertson W, et al. Bile acids stimulate proliferative and secretory events in large but not small cholangiocytes. Am J Physiol. 1997;273:G518–G529
  31. Alpini G, Baiocchi L, Glaser S, et al. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology. 2002;35:1041–1052
  32. Marzioni M, Ueno Y, Glaser S, et al. Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver. Liver Int. 2007;27:558–568
  33. Marzioni M, LeSage G, Glaser S, et al. Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct ligated rats. Am J Physiol. 2003;284:G837–G852
  34. Marucci L, Alpini G, Glaser SS, et al. Taurocholate feeding prevents CCl4-induced damage of large cholangiocytes through PI3-kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 2003;284:G290–G301
  35. Marzioni M, Francis H, Benedetti A, et al. Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol. 2006;168:398–409
  36. Alpini G, Glaser S, Alvaro D, et al. Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinase-dependent pathway in rats. Gastroenterology. 2002;123:1226–1237
  37. Nathanson MH, Burgstahler AD, Mennone A, et al. Characterization of cytosolic Ca2+ signaling in rat bile duct epithelia. Am J Physiol. 1996;271:G86–G96
  38. LeSage G, Alvaro D, Benedetti A, et al. Cholinergic system modulates growth, apoptosis and secretion of cholangiocytes from bile duct ligated rats. Gastroenterology. 1999;117:191–199
  39. Iwai M, Shimazu T. Alteration in sympathetic nerve activity during liver regeneration in rats after partial hepatectomy. J Auton Nerv Syst. 1992;41:209–214
  40. LeSage GD, Alvaro D, Glaser S, et al. Alpha-1 adrenergic receptor agonists modulate ductal secretion of BDL rats via Ca(2+)- and PKC-dependent stimulation of cAMP. Hepatology. 2004;40:1116–1127
  41. Francis H, LeSage G, Demorrow S, et al. The {alpha}2-adrenergic receptor agonist UK 14,304 inhibits secretin-stimulated ductal secretion by downregulation of the cAMP system in bile duct-ligated rats. Am J Physiol Cell Physiol. 2007;293:C1252–C1262
  42. Glaser S, Alvaro D, Francis H, et al. Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. Am J Physiol Gastrointest Liver Physiol. 2006;290:G813–G826
  43. Fava G, Marzioni M, Francis H, et al. Novel interaction of bile acid and neural signaling in the regulation of cholangiocyte function. Hepatol Res. 2007;37(Suppl. 3):S420–S429
  44. Alvaro D, Alpini G, Onori P, et al. Effect of ovariectomy on the proliferative capacity of intrahepatic rat cholangiocytes. Gastroenterology. 2002;123:336–344
  45. Alvaro D, Alpini G, Onori P, et al. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology. 2000;119:1681–1691
  46. Marzioni M, Glaser S, Francis H, et al. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology. 2005;128:121–137
  47. Marzioni M, Svegliati Baroni G, Alpini G, et al. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol. 2007;46:583–586
  48. Bergasa NV, Liau S, Homel P, et al. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver. 2002;22:107–113
  49. Bergasa NV, Rothman RB, Vergalla J, et al. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol. 1992;15:220–224
  50. Bergasa NV, Vergalla J, Swain MG, et al. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver. 1996;16:298–302
  51. Swain MG, Rothman RB, Xu H, et al. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology. 1992;103:630–635
  52. Bergasa NV, Sabol SL, Young WS, et al. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol. 1995;268:G346–G354
  53. Marzioni M, Alpini G, Saccomanno S, et al. Endogenous opioids modulate the growth of the biliary tree in the course of cholestasis. Gastroenterology. 2006;130:1831–1847
  54. Alvaro D, Metalli VD, Alpini G, et al. The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 axis. J Hepatol. 2005;43:875–883
  55. Gaudio E, Barbaro B, Alvaro D, et al. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology. 2006;130:1270–1282
  56. Gaudio E, Barbaro B, Alvaro D, et al. Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. Am J Physiol Gastrointest Liver Physiol. 2006;291:G307–G317
  57. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122:531–544
  58. Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology. 2007;133:244–255
  59. Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut. 2009;58:990–997
  60. Bulotta A, Hui H, Anastasi E, et al. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol. 2002;29:347–360
  61. Zhou J, Wang X, Pineyro MA, et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes. 1999;48:2358–2366
  62. Nagaya M, Kubota S, Isogai A, et al. Ductular cell proliferation in islet cell neogenesis induced by incomplete ligation of the pancreatic duct in dogs. Surg Today. 2004;34:586–592
  63. Yang L, Li S, Hatch H, et al. In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc Natl Acad Sci USA. 2002;99:8078–8083
  64. Hanada S, Harada M, Koga H, et al. Tumor necrosis factor-alpha and interferon-gamma directly impair epithelial barrier function in cultured mouse cholangiocytes. Liver Int. 2003;23:3–11
  65. Spirli C, Fabris L, Duner E, et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology. 2003;124:737–753
  66. Spirli C, Nathanson MH, Fiorotto R, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology. 2001;121:156–169
  67. Morland CM, Fear J, McNab G, et al. Promotion of leukocyte transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro. Proc Assoc Am Physicians. 1997;109:372–382
  68. Heydtmann M, Lalor PF, Eksteen JA, et al. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol. 2005;174:1055–1062
  69. Eksteen B, Miles A, Curbishley SM, et al. Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J Immunol. 2006;177:593–603
  70. Xu B, Broome U, Ericzon BG, et al. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut. 2002;51:120–127
  71. Karrar A, Broome U, Sodergren T, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology. 2007;132:1504–1514
  72. Bioulac-Sage P, Lafon ME, Saric J, et al. Nerves and perisinusoidal cells in human liver. J Hepatol. 1990;10:105–112
  73. Salas JT, Banales JM, Sarvide S, et al. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology. 2008;134:1482–1493
  74. Poupon R, Ping C, Chretien Y, et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol. 2008;49:1038–1045
  75. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267
  76. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology. 2002;123:1238–1251
  77. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2004;127:261–274
  78. Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2006;130:465–481
  79. Halilbasic E, Fiorotto R, Fickert P, et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice. Hepatology. 2009;49:1972–1981
  80. Buis CI, Geuken E, Visser DS, et al. Altered bile composition after liver transplantation is associated with the development of nonanastomotic biliary strictures. J Hepatol. 2009;50:69–79
  81. Alvaro D, Invernizzi P, Onori P, et al. Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol. 2004;41:905–912
  82. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology. 1999;29:1003–1006
  83. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Br Med J. 1988;297:1501–1504
  84. Bergasa NV, Thomas DA, Vergalla J, et al. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci. 1993;53:1253–1257
  85. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. Q J Med. 2002;95:547–552
  86. Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666–674
  87. Marzioni M, Invernizzi P, Candelaresi C, et al. Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. Dig Liver Dis. 2009;41:523–533
  88. Alpini G, Invernizzi P, Gaudio E, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 2008;68:9184–9193
  89. Washington K, Clavien PA, Killenberg P. Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis. Hum Pathol. 1997;28:791–795
  90. Beaussier M, Wendum D, Schiffer E, et al. Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. Lab Invest. 2007;87:292–303
  91. Alvaro D, Barbaro B, Franchitto A, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006;169:877–888
  92. Mancino A, Mancino MG, Glaser SS, et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis. 2009;41:156–163
  93. Alvaro D, Macarri G, Mancino MG, et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med. 2007;147:451–459
  94. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc. 2007;298:194–206
  95. Beuers U, Goke B. GLP-1 analogues: a new therapeutic approach to prevent ductopenia in cholangiopathies?. Gut. 2009;58:902–903
  96. Sasatomi K, Noguchi K, Sakisaka S, et al. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 1998;29:409–416
  97. Fava G, Alpini G, Rychlicki C, et al. Leptin enhances cholangiocarcinoma cell growth. Cancer Res. 2008;68:6752–6761
  98. Fickert P, Stoger U, Fuchsbichler A, et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol. 2007;171:525–536

☆ This work was supported by a MIUR grant 2007—prot. 2007HPT7BA_002 to Dr. Marzioni and by Intramural Grants by the Università Politecnica delle Marche to Dr. Marzioni and to Dr. Benedetti.

PII: S1590-8658(10)00009-5

doi: 10.1016/j.dld.2010.01.005

Digestive and Liver Disease
Volume 42, Issue 4 , Pages 238-244 , April 2010

Article Tools